Reflecting on COVID-19: The Hong Kong Experience of Flattening the Curve Without Lockdown by Herbert H. Loong

Get full text

Developing Drugs for Sarcomas in a Brave New World by Herbert H. Loong

Get full text

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong by Herbert H. Loong, Carlos K. H. Wong, Linda K. S. Leung, Catherine P. K. Chan, Andrea Chang, Zheng-Yi Zhou, Jipan Xie, Meaghan Gibbs

Get full text

Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong by Herbert H. Loong, Carlos K. H. Wong, Linda K. S. Leung, S. C. Tan, Jason Jen, Mary Y. K. Lee, Raquel Aguiar-Ibáñez, Jingshu Wang

Get full text

Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia by Herbert H. Loong, MBBS, FRCP, Carlos K.H. Wong, PhD, Catherine P.K. Chan, PharmD, Andrea Chang, MBA, Zheng-Yi Zhou, PhD, Wenxi Tang, MS, Meaghan Gibbs, MSc

Get full text

Proceedings of the 3rd Chinese University of Hong Kong (CUHK) Sarcoma Masterclass, September 21, 2019 by Herbert H. Loong, Angela Hong, Alex W.H. Ng, Maribel D. Lacambra, Wang-kei Chiu, Teresa Tse, Darren M.C. Poon, Teresa Tan, Cina Tong, Jeremy Yip, Roger K.C. Ngan, Shekhar Kumta, K.C. Wong

Get full text